Research Paper Volume 16, Issue 2 pp 1536—1554

Figure 8. Study of the efficacy of drug therapy for low-risk and high-risk patients. (A) In the low-risk groups, treatment scores for BIBR-1532, GDCO-810, I-BRD9, IAP-5620, Lapatinib and Sapitinib were higher than in the high-risk groups. (P < 0.001). (B) In the low-risk groups, treatment scores for ULK-14989, UMI-77, and Afatinib were higher than in the high-risk groups (P < 0.001). (C) Foretinib, Gemcitabine, and ERK-2440 treatment scores in the high-risk groups were higher than in the low-risk groups (P < 0.01). (D) JAK1-8709 and Nutlin-3a(-) treatment scores were higher in high-risk groups than in low-risk groups (P < 0.001). Statistical significance is indicated by an asterisk: ^*p < 0.05; ^**p < 0.01 and ^***p < 0.001.